There comes a time when great companies reach a sell range. In our view, Abbott Laboratories (NYSE:ABT) just approached that mark.
After highlighting the fundamental and technical aspects of Abbott back at $47 on Sept. 24, 2009, in an update and actively accumulating the stock near the Jan. 31, 2011, low, the stock has risen 47% since 2009 and 53% since 2011 (excluding dividends). The annualized return is equivalent to +13.89% since 2009 and +28% since 2011. The stock outpaced the S&P 500 by roughly 13% from our 2009 review and by 37% since our early 2011 article.
Click to enlarge image.
Let's revisit our original assessment of Abbott in 2009. The stock was trading at 14 times earnings and 10 times cash flow, and was sporting a 3.4% dividend yield. Today, Abbott is currently trading at 22 times earnings and 12 times cash flow, and has a 3.0% dividend yield. The table below shows a summary of the relative change that has occurred since 2009.
While our valuation model shows that Abbott is undervalued at a 3% dividend yield, 13 times earnings, and 10 times cash flow, we'd rather recommend selling the stock only if purchased near the $45-$47 price range as indicated in the article linked to above.
Those not interested in following through with our sell recommendation can feel comfortable knowing that Abbott is a great long-term holding, with a minimum 40% downside cushion since our 2009 review. It's no doubt that income investors can hold shares of Abbott knowing that the dividend will be safe and will continue to grow. Anyone who bought Abbott at $47 would be sitting on a yield on cost of 4.3%. Not too bad when the 10-year Treasury bill is close to zero.
In any event, we believe it may be a good time to offload shares of Abbott by either selling the entire position or selling the principle while letting the profit run.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.